ABBOTT PARK, Illinois and IRVING, Texas, December 12, 2011 - - Agreement Calls for 50/50 Global Profit Share for Multiple New Molecules - Companies Plan to Explore Broad Therapeutic Potential of AIM Class Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs).

ABBOTT PARK, Illinois, December 9, 2011 - The board of directors of Abbott (NYSE: ABT)today declared a quarterly common dividend of 48 cents per share.

ABBOTT PARK, Illinois, December 8, 2011 - Abbott (NYSE: ABT) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.

DES PLAINES, Illinois, November 28, 2011 - Abbott (NYSE: ABT)announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A.

ABBOTT PARK, Illinois, November 14, 2011 - -- Long-Term Clinical Results for the Investigational ABSORB Device are Consistent with Earlier Reported Data in the ABSORB Trial -- Low Late Loss of 0.27 mm at Two Years; Comparable to Results Seen at One Year -- Two-Year Imaging Results Show the Vessel Remains Open without the Need for Scaffold Support Abbott (NYSE: ABT) today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.
Older News
27 28 29 30 1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
Copyright© 2011 The Gaea Times